Gossamer Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Gossamer Bio, Inc. (GOSS) on July 14, 2026. The report details the results of a Special Meeting of Stockholders held on the same date, focusing on corporate governance changes, capital structure adjustments, and the approval of an amended equity incentive plan.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin data. However, it references the following capital structure elements:
- Existing Debt: $200.0 million aggregate principal amount of 5.00% Convertible Senior Notes due 2027 (Existing Convertible Notes), which were the subject of an Exchange Offer that closed on June 4, 2026.
- New Debt: Issuance of 7.50% Convertible Senior Secured First Lien Notes due 2030 (New Convertible Notes) as part of the Exchange Offer.
- Equity Instruments: Issuance of Purchase Warrants to purchase 135,789,000 shares of Common Stock.
Material Changes
The following material changes were approved by stockholders and implemented as of July 14, 2026:
- Authorized Share Increase: The Company filed a Charter Amendment to increase authorized Common Stock from 700,000,000 to 4,000,000,000 shares. This supports potential issuances from the New Convertible Notes, Purchase Warrants, and the Restated Plan.
- Equity Incentive Plan: Stockholders approved the Restated 2019 Incentive Award Plan, increasing the number of shares authorized for issuance.
- Reverse Stock Split Approval: Stockholders approved a series of 30 alternate amendments to effect a reverse stock split and a proportionate reduction in authorized shares, though the filing does not specify if this was immediately executed.
- Exchange Offer Completion: The Exchange Offer for the Existing Convertible Notes closed on June 4, 2026, via early settlement with no additional notes tendered thereafter.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or specific risk factors beyond the standard disclosures regarding the potential dilution from the New Convertible Notes and Purchase Warrants. The primary focus is on the successful completion of the Exchange Offer and the necessary corporate amendments to facilitate future share issuances.
Investor Verification Checklist
- Verify the specific terms and conversion rates of the new 7.50% Convertible Senior Secured First Lien Notes due 2030.
- Confirm the exact number of shares added to the 2019 Incentive Award Plan under the Restated Plan.
- Review the implementation status of the approved reverse stock split and the resulting share count.
- Assess the impact of the 135,789,000 Purchase Warrants on future dilution.
- Examine the full text of the Charter Amendment (Exhibit 3.1) and Restated Plan (Exhibit 10.1) for detailed provisions.